Volver al buscador
FDAFDA · Alimentos y medicamentos·N.º oficial Z-0506-2013

Siemens Healthcare BNP (8-type Natriuretic Peptide) 500 Test kit 02816634 100 Test 02816138 10309045, 10309044 028 Intended Use For in vitro diagnostic use in the quantitative determination of B-type Natriuretic Peptide (BNP) in human plasma using the ADVIA Centaur and ADVIA Centaur XP systems. This assay is indicated for the measurement of plasma BNP as an aid in the diagnosis and assessment of the severity of heart failure. In patients with acute coronary syndromes (ACS), this test, in conjunction with other known risk factors, can also be used to predict survival as well as to predict the likelihood of future heart failure.

Publicado el 19 de diciembre de 2012 · Inicio del retiro: 14 de noviembre de 2012

Resumen

FDA registra el retiro Z-0506-2013 de dispositivos médicos de Clase II, publicado el 19 de diciembre de 2012 e iniciado el 14 de noviembre de 2012. Empresa responsable: Siemens Healthcare Diagnostics, Inc; Estado: Finalizado; Cantidad reportada: 100 test=24291 and 500 test= 9679; Lote: All lot codes. La Clase II indica posibles consecuencias temporales o médicamente reversibles, o una probabilidad remota de consecuencias graves.

Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.

Qué peligro representa

Operating range of the ADVIA Centaur systems is 18®C to 30®C (64.4®F to 86.0®F), a change in room temperature may increase or decrease assay results, depending on the specific assay and ADVIA Centaur system used.

Qué hacer

Voluntary: Firm initiated · Letter

Recibe un correo cuando FDA publique un retiro como este

Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.

Detalles del retiro

Fabricante
Siemens Healthcare Diagnostics, Inc
Distribuidor
Worldwide Distribution - USA (nationwide) and Internationally to the following countries: Argentina Australia Austria Azerbaijan Belgium Bosnia Herzeg. Brazil Canada Chile COLOMBIA Croatia Czech Republic Denmark Egypt Estonia Finland France Germany Greece Hong Kong Hungary Iceland India Indonesia Iran Ireland Italy Japan Kazakhstan Latvia Lithuania Malaysia Mexico Netherlands New Caledonia Norway Oman P.R. China Philippines Poland Portugal Qatar Rep. of Yemen Republic Korea Reunion Romania Russian Fed. Saudi Arabia Serbia Slovakia Slovenia South Africa Spain Sweden Switzerland Taiwan Thailand Turkey U.A.E. United Kingdom Uruguay Vietnam
Lote
All lot codes
Clasificación de riesgo
Class II
Área (FDA)
device
País
United States

Retiros relacionados

Preguntas sobre este retiro

¿Siemens Healthcare BNP (8-type Natriuretic Peptide) 500 Test kit 02816634 100 Test 02816138 10309045, 10309044 028 Intended Use For in vitro diagnostic use in the quantitative determination of B-type Natriuretic Peptide (BNP) in human plasma using the ADVIA Centaur and ADVIA Centaur XP systems. This assay is indicated for the measurement of plasma BNP as an aid in the diagnosis and assessment of the severity of heart failure. In patients with acute coronary syndromes (ACS), this test, in conjunction with other known risk factors, can also be used to predict survival as well as to predict the likelihood of future heart failure. fue retirado del mercado?

Sí. FDA publicó el retiro Z-0506-2013 el 19 de diciembre de 2012. Peligro reportado: Operating range of the ADVIA Centaur systems is 18®C to 30®C (64.4®F to 86.0®F), a change in room temperature may increase or decrease assay results, depending on the specific assay and ADVIA Centaur system used.

¿Qué debo hacer si tengo este producto?

Voluntary: Firm initiated · Letter